Table 1.
Baseline characteristics by study arm among breast cancer survivors enrolled in a randomized trial of physical activity (N=87).
| Baseline characteristics | Exercise intervention (n=43) | Wellness control (n=44) | P value | ||
| Demographicsa | |||||
|
|
Age (years), mean (SD) | 58.2 (11.37) | 56.2 (9.30) | .35 | |
|
|
Education, n (%) | .69 | |||
|
|
|
Some college or less | 14 (33) | 11 (25) | —b |
|
|
|
College graduate | 18 (42) | 22 (50) | — |
|
|
|
Master’s degree or higher | 11 (26) | 11 (25) | — |
|
|
Married or living with partner, n (%) | 32 (76) | 31 (71) | .68 | |
|
|
Ethnicity, n (%) | .74 | |||
|
|
|
Not Hispanic or Latino | 35 (81) | 37 (84) | — |
|
|
|
Hispanic or Latino | 8 (19) | 7 (16) | — |
|
|
Race, n (%) | .62 | |||
|
|
|
White | 36 (84) | 35 (80) | — |
|
|
|
Nonwhite | 7 (16) | 10 (23) | — |
| Body mass index (kg/m2), mean (SD) | 26.7 (6.20) | 27.3 (6.40) | .63 | ||
| Time since breast cancer surgery (months), mean (SD) | 30.3 (17.41) | 30.0 (16.08) | .99 | ||
| Cancer stage, n (%) | .79 | ||||
|
|
Stage 1 | 27 (63) | 26 (59) | — | |
|
|
Stage 2 | 12 (28) | 15 (34) | — | |
|
|
Stage 3 | 4 (9) | 3 (7) | — | |
| Received chemotherapy, n (%) | 23 (54) | 23 (52) | .91 | ||
| Current aromatase inhibitor or tamoxifen, n (%) | 31 (72) | 30 (68) | .69 | ||
| Physical and psychological functioning, mean (SD) | |||||
|
|
Physical functioning | 50.2 (7.49) | 51.8 (6.84) | .32 | |
|
|
Anxiety | 54.8 (8.51) | 55.6 (6.95) | .65 | |
|
|
Depression | 50.0 (8.16) | 50.7 (7.88) | .68 | |
|
|
Fatigue | 52.5 (7.64) | 54.4 (9.17) | .29 | |
| Biomarkersc, mean (SD) | |||||
|
|
Brain-derived neurotropic factor, normalized values | 0.3 (0.19) | 0.3 (0.29) | .32 | |
|
|
Homeostatic model assessment 2 of insulin resistance | 1.2 (0.98) | 1.4 (1.12) | .58 | |
|
|
Log C-reactive protein (pg/mL) | 14.3 (1.29) | 14.6 (1.32) | .31 | |
| Cognitiona, mean (SD) | |||||
|
|
Neurocognitive testing: processing speed (raw score) | 73.7 (14.55) | 77.7 (13.23) | .19 | |
|
|
Self-reported cognitive abilities (T-score) | 46.6 (5.96) | 44.3 (5.27) | .06 | |
aA secondary analysis of the mechanisms underlying the effect of an intervention on cognition is displayed here. The main effects of the intervention on cognition were previously published in a study by Hartman et al [7]
bNot applicable.
cBiomarker values were log transformed before analysis to correct for right-skewed residuals.